EANM during my presidency?

During my presidency the nuclear medicine community faced 4 major challenges:

Shortage of reactor-produced radionuclide supply, hybrid imaging, justification of our field to be an independent medical specialty, and deficit in representation of young medical scientists in Committees.

Strategies to respond to these challenges were

• Lobbying for support of reactors in Europe dedicated to production of medical radionuclides, in particular of Mo-99, on different levels of European policy makers (DG Energy, DG Health, European Parliament, and Council).
• Agreement with the European Society of Radiology on educational requirements to perform and evaluate hybrid imaging exams such as PET/CT or SPECT/CT (commonly approved White Paper).
• Identification of common strategic interests with radiation oncology as represented by the ESTRO and inauguration of a novel congress format, MIRO (Molecular Imaging in Radiation Oncology).
• Establishment of Interest Groups for EANM Committees.

EANM now and in future?

Since its foundation the EANM has gone an enormously successful way. It has definitely become a more important scientific platform in our field than any of the national societies in Europe, and it appears to be the most powerful representative of nuclear medicine in the world. Accordingly, the EANM Congresses now attract more attendees from all over the world and more than any other congress in the field. In addition the official Journal, European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) is actually the most highly ranked publication organ for nuclear medicine in the world. One of the success factors, apart from excellent governing of the organisation, is the ongoing strong position held by nuclear medicine in the European health environment and in the medical faculties of universities as well as in European research centers. As radionuclide therapy together with theranostics has experienced a dramatic increase in attention by researchers and clinicians of a variety of medical specialties, nuclear medicine will consolidate or even strengthen its position in future, and since relevant innovations were initiated in Europe, the EANM disposes at the fundamentals to remain the leading scientific nuclear medicine organisation in future.
What is EANM for me?

For me having retired from my positions at university and hospital, EANM meetings are a place for reminiscences and communication with colleagues who accompanied an important part of my life. I am pleased to have the opportunity to still lend some support for the awareness of principles of transparency and ethics together with the Members of the Ethics Committee. The EANM has become one of some major learned societies having recognised the importance of disclosing and managing financial and non-financial interests by their officers and mandate holders. Transparency and effective management of conflicts of interest as pursued by the EANM have become keys to credibility and public acceptance of any kind of statements by scientific organisations.